{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056179","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.189858+00:00","generated_at":"2026-06-28T09:46:56.831235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M","bullets":["Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.","Cash, cash equivalents and investments $116.4M at Sept 30, 2021, after $80.6M net from stock offering.","R&D expenses $5.1M and G&A $2.6M for Q3 2021; 27.8M shares outstanding.","Appointed Robert W. Ashworth, PhD, as VP of Regulatory Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056179","json":"https://secwatch.observer/filing/0001564590-21-056179.json","markdown":"https://secwatch.observer/filing/0001564590-21-056179.md","text":"https://secwatch.observer/filing/0001564590-21-056179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/0001564590-21-056179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/life-8k_20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:46:56.831235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}